EE04852B1 - C-21 modifitseeritud epotioloonid, nende valmistamise meetod ning kasutamine ja ravimkoostise kasutamine vähkkasvajate või teiste proliferatiivsete haiguste ravimisel - Google Patents

C-21 modifitseeritud epotioloonid, nende valmistamise meetod ning kasutamine ja ravimkoostise kasutamine vähkkasvajate või teiste proliferatiivsete haiguste ravimisel

Info

Publication number
EE04852B1
EE04852B1 EEP200100437A EEP200100437A EE04852B1 EE 04852 B1 EE04852 B1 EE 04852B1 EE P200100437 A EEP200100437 A EE P200100437A EE P200100437 A EEP200100437 A EE P200100437A EE 04852 B1 EE04852 B1 EE 04852B1
Authority
EE
Estonia
Prior art keywords
epothiolones
cancerous
modified
treatment
making
Prior art date
Application number
EEP200100437A
Other languages
English (en)
Estonian (et)
Inventor
Hoefle Gerhard
Glaser Nicole
Leibold Thomas
D. Vite Gregory
Kim Soong-Hoon
Original Assignee
Gesellschaft Fuer Biotechnologische Forschung Mbh
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1999107588 external-priority patent/DE19907588A1/de
Priority claimed from DE1999130111 external-priority patent/DE19930111A1/de
Application filed by Gesellschaft Fuer Biotechnologische Forschung Mbh, Bristol-Myers Squibb Company filed Critical Gesellschaft Fuer Biotechnologische Forschung Mbh
Publication of EE200100437A publication Critical patent/EE200100437A/xx
Publication of EE04852B1 publication Critical patent/EE04852B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
EEP200100437A 1999-02-22 2000-02-17 C-21 modifitseeritud epotioloonid, nende valmistamise meetod ning kasutamine ja ravimkoostise kasutamine vähkkasvajate või teiste proliferatiivsete haiguste ravimisel EE04852B1 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE1999107588 DE19907588A1 (de) 1999-02-22 1999-02-22 C-21 Modifizierte Epothilone
DE1999130111 DE19930111A1 (de) 1999-07-01 1999-07-01 C-21 Modifizierte Epothilone
PCT/US2000/004068 WO2000050423A1 (en) 1999-02-22 2000-02-17 C-21 modified epothilones

Publications (2)

Publication Number Publication Date
EE200100437A EE200100437A (et) 2002-12-16
EE04852B1 true EE04852B1 (et) 2007-06-15

Family

ID=26051995

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100437A EE04852B1 (et) 1999-02-22 2000-02-17 C-21 modifitseeritud epotioloonid, nende valmistamise meetod ning kasutamine ja ravimkoostise kasutamine vähkkasvajate või teiste proliferatiivsete haiguste ravimisel

Country Status (37)

Country Link
US (1) US6262094B1 (pl)
EP (1) EP1157023B1 (pl)
JP (1) JP4598957B2 (pl)
KR (1) KR100685336B1 (pl)
CN (1) CN1205208C (pl)
AR (1) AR028815A1 (pl)
AT (1) ATE254615T1 (pl)
AU (1) AU771089B2 (pl)
BG (1) BG64987B1 (pl)
BR (1) BR0008379A (pl)
CA (1) CA2360452C (pl)
CO (1) CO5140093A1 (pl)
CZ (1) CZ301498B6 (pl)
DE (1) DE60006649T2 (pl)
DK (1) DK1157023T3 (pl)
EE (1) EE04852B1 (pl)
ES (1) ES2209831T3 (pl)
GE (1) GEP20033067B (pl)
HK (1) HK1038923B (pl)
HU (1) HUP0200076A3 (pl)
ID (1) ID29829A (pl)
IL (1) IL144501A0 (pl)
LT (1) LT4944B (pl)
LV (1) LV12755B (pl)
MX (1) MXPA01008374A (pl)
MY (1) MY120601A (pl)
NO (1) NO320806B1 (pl)
NZ (1) NZ513629A (pl)
PE (1) PE20001546A1 (pl)
PL (1) PL212545B1 (pl)
PT (1) PT1157023E (pl)
RU (1) RU2253652C2 (pl)
SK (1) SK287200B6 (pl)
TR (1) TR200102401T2 (pl)
TW (1) TWI270546B (pl)
UY (1) UY26024A1 (pl)
WO (1) WO2000050423A1 (pl)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59712968D1 (de) 1996-11-18 2008-10-30 Biotechnolog Forschung Gmbh Epothilone E und F
AU756699B2 (en) 1996-12-03 2003-01-23 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
GB9810659D0 (en) * 1998-05-18 1998-07-15 Ciba Geigy Ag Organic compounds
US6780620B1 (en) * 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
US6589968B2 (en) * 2001-02-13 2003-07-08 Kosan Biosciences, Inc. Epothilone compounds and methods for making and using the same
CZ2003845A3 (cs) 2000-09-22 2003-08-13 Gesellschaft Für Biotechnologische Forschung Mbh ( Triazolo-epothilony
CA2425828A1 (en) * 2000-10-13 2002-04-18 The University Of Mississippi Synthesis of epothilones and related analogs
JP2004521122A (ja) 2001-01-25 2004-07-15 ブリストル−マイヤーズ　スクイブ　カンパニー エポチロン類似体の非経口製剤
US6893859B2 (en) 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
PL363363A1 (pl) * 2001-02-20 2004-11-15 Bristol-Myers Squibb Company Pochodne epotilonu do leczenia opornych guzów
HUP0303175A2 (hu) 2001-02-20 2003-12-29 Bristol-Myers Squibb Co. Epotilonszármazékok alkalmazása makacs tumorok kezelésére alkalmas gyógyszerkészítmény előállítására
KR20040025904A (ko) 2001-03-14 2004-03-26 브리스톨-마이어스 스큅 컴퍼니 증식성 질환의 치료를 위한 에포틸론 유사체 및화학치료제의 병용
TWI341728B (en) * 2002-01-14 2011-05-11 Novartis Ag Combinations comprising epothilones and anti-metabolites
TW200303202A (en) 2002-02-15 2003-09-01 Bristol Myers Squibb Co Method of preparation of 21-amino epothilone derivatives
WO2003074521A1 (en) * 2002-03-01 2003-09-12 University Of Notre Dame Derivatives of epothilone b and d and synthesis thereof
EP1854464A3 (en) * 2002-03-08 2008-06-04 Novartis AG Combinations comprising epothilone derivatives and alkylating agents
IL163774A0 (en) * 2002-03-08 2005-12-18 Univ Newcastle Combinations comprising epothilone derivatives andalkylating agents
AU2003218107A1 (en) * 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
WO2003078411A1 (en) 2002-03-12 2003-09-25 Bristol-Myers Squibb Company C3-cyano epothilone derivatives
TW200403994A (en) * 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
PL211114B1 (pl) * 2002-05-01 2012-04-30 Novartis Ag Zastosowanie pochodnej epotilonowej w leczeniu choroby nowotworowej
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
NZ538522A (en) 2002-08-23 2008-03-28 Sloan Kettering Inst Cancer Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) * 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
RS20050235A (sr) * 2002-09-23 2007-06-04 Bristol Myers Squibb Company, Postupci za pripremanje,izolaciju i prečišćavanje epotilona b i kristalne strukture epotilona b dobijene primenom x-zraka
MXPA05003706A (es) * 2002-10-09 2005-07-01 Kosan Biosciences Inc Epo d+5-fu/gemcitabina.
US7169771B2 (en) 2003-02-06 2007-01-30 Bristol-Myers Squibb Company Thiazolyl-based compounds useful as kinase inhibitors
US20050171167A1 (en) 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US7420059B2 (en) * 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
EP1559447A1 (en) 2004-01-30 2005-08-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
GB0405898D0 (en) 2004-03-16 2004-04-21 Novartis Ag Organic compounds
US7459562B2 (en) * 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) * 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US20090004277A1 (en) * 2004-05-18 2009-01-01 Franchini Miriam K Nanoparticle dispersion containing lactam compound
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7432373B2 (en) * 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7439246B2 (en) * 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
EP1824458A1 (en) * 2004-11-18 2007-08-29 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
EP1817013B1 (en) * 2004-11-18 2008-06-04 Brystol-Myers Squibb Company Enteric coated bead comprising ixabepilone
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Ｂｉｒドメイン結合化合物
CA2628227A1 (en) * 2005-11-22 2007-05-31 The Scripps Research Institute Chemical synthesis of a highly potent epothilone
US7348325B2 (en) 2005-11-30 2008-03-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
JP5419685B2 (ja) 2006-05-16 2014-02-19 ファーマサイエンス・インコーポレイテッド Ｉａｐｂｉｒドメイン結合タンパク質
WO2008109075A2 (en) * 2007-03-05 2008-09-12 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to ctla-4 antagonists
JP2010528115A (ja) * 2007-05-25 2010-08-19 ブリストル−マイヤーズ スクイブ カンパニー エポチロン化合物およびアナログの製造方法
EP2227296B1 (en) 2008-01-08 2015-11-25 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with tubulin modulating agents for the treatment of proliferative diseases
PL2276485T3 (pl) * 2008-04-24 2014-12-31 Bristol Myers Squibb Co Stosowanie epotilonu D w leczeniu chorób związanych z Tau, w tym choroby Alzheimera
US20090311187A1 (en) * 2008-05-29 2009-12-17 Bristol-Myers Squibb Company Methods for predicting patient response to modulation of the Co-stimulatory pathway
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
MX2012000851A (es) 2009-07-20 2012-06-08 Squibb Bristol Myers Co Combinacion de anticuerpo de anti-antigeno 4 asociado al linfocito t citotoxico con diversos regimenes terapeuticos para tratamiento sinergistico de enfermedades proliferativas.
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
CA2779574C (en) 2009-11-05 2018-12-18 Rhizen Pharmaceuticals S.A. Novel kinase modulators
MX340870B (es) 2010-02-12 2016-07-27 Pharmascience Inc Compuestos de unión del dominio de repetición de inhibidores de proteínas de apoptosis de baculovirus.
EP2571577A1 (en) 2010-05-17 2013-03-27 Bristol-Myers Squibb Company Improved immunotherapeutic dosing regimens and combinations thereof
DK2571878T3 (en) 2010-05-17 2019-02-11 Indian Incozen Therapeutics Pvt Ltd Hitherto unknown 3,5-DISUBSTITUTED-3H-IMIDAZO [4,5-B] PYRIDINE AND 3,5- DISUBSTITUTED -3H- [1,2,3] TRIAZOL [4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF PROTEIN CHINES
EA035193B1 (ru) 2010-05-18 2020-05-14 Серулин Фарма Инк. Композиции и способы лечения аутоиммунных и других заболеваний
HRP20190128T1 (hr) 2011-05-04 2019-03-08 Rhizen Pharmaceuticals S.A. Novi spojevi kao modulatori protein kinaza
CN102863474A (zh) 2011-07-09 2013-01-09 陈小平 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
CN102993239A (zh) 2011-09-19 2013-03-27 陈小平 离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
KR20140144726A (ko) 2012-03-30 2014-12-19 리젠 파마슈티컬스 소시에떼 아노님 C-met 단백질 키나제의 조절제로서의 신규한 3,5-디치환-3h-이미다조[4,5-b]피리딘 및 3,5- 디치환 -3h-[1,2,3]트리아졸로[4,5-b] 피리딘 화합물
US9725477B2 (en) 2012-11-17 2017-08-08 Beijing Fswelcome Technology Development Co., Ltd Platinum compounds of malonic acid derivative having leaving group containing amino or alkylamino
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
EP2972394A4 (en) 2013-03-15 2016-11-02 Sloan Kettering Inst Cancer HSP90-DESIGNING AND THERAPY
EP3066127A1 (en) 2013-11-06 2016-09-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
MX2017007097A (es) 2014-12-04 2017-09-05 Bristol Myers Squibb Co Combinacion de anticuerpos anti-cs1 y anti-muerte programada 1 (pd1) para tratar cancer (mieloma).
PL3313528T3 (pl) 2015-06-29 2021-12-13 Bristol-Myers Squibb Company Schematy dawkowania immunoterapeutycznego obejmujące pomalidomid i przeciwciało anty-cs1 w leczeniu raka
CN105153177B (zh) * 2015-09-28 2017-08-08 湖南大学 呋喃并色满肟烯/炔丙基醚及其制备方法与应用
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE301115C (pl)
DE75883C (de) W. schulte in Siegen und F. A. SAPP in Hillnhütten, Kreis Siegen Ofen zur Erzeugung von Cyanammonium
GB8909737D0 (en) * 1989-04-27 1989-06-14 Shell Int Research Thiazole derivatives
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
DE19542986A1 (de) 1995-11-17 1997-05-22 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Verwendung
DE19639456A1 (de) 1996-09-25 1998-03-26 Biotechnolog Forschung Gmbh Epothilon-Derivate, Herstellung und Mittel
DE59610712D1 (de) 1995-11-17 2003-10-16 Biotechnolog Forschung Gmbh Epothilonderivate, herstellung und verwendung
WO1998008849A1 (de) 1996-08-30 1998-03-05 Novartis Aktiengesellschaft Verfahren zur herstellung von epothilonen und zwischenprodukte innerhalb des verfahrens
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
DE19636343C1 (de) 1996-08-30 1997-10-23 Schering Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
DE59712968D1 (de) * 1996-11-18 2008-10-30 Biotechnolog Forschung Gmbh Epothilone E und F
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
AU756699B2 (en) 1996-12-03 2003-01-23 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6441186B1 (en) * 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
DE19707303B4 (de) 1997-02-11 2006-05-11 Mitteldeutsches Bitumenwerk Gmbh Verfahren zur Gewinnung von Mikrowachsen, Paraffinen und Ölen aus Altkunststoffen oder Altkunststoffgemischen
DE59805110D1 (de) 1997-02-25 2002-09-12 Biotechnolog Forschung Gmbh Seitenkettenmodifizierte epothilone
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
CA2286610C (en) 1997-04-18 2007-03-13 Studiengesellschaft Kohle Mbh Selective olefin metathesis of bifunctional or polyfunctional substrates in compressed carbon dioxide as reaction medium
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
WO1999003848A1 (de) 1997-07-16 1999-01-28 Schering Aktiengesellschaft Thiazolderivate, verfahren zur herstellung und verwendung
ATE368036T1 (de) 1997-08-09 2007-08-15 Bayer Schering Pharma Ag Neue epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung
US6498257B1 (en) * 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
KR20010092453A (ko) * 1998-12-23 2001-10-25 스티븐 비. 데이비스 에포틸론 제조를 위한 미생물적 전환 방법

Also Published As

Publication number Publication date
TWI270546B (en) 2007-01-11
PE20001546A1 (es) 2001-03-18
JP2002537395A (ja) 2002-11-05
US6262094B1 (en) 2001-07-17
CA2360452C (en) 2011-07-26
EP1157023B1 (en) 2003-11-19
KR100685336B1 (ko) 2007-02-23
EP1157023A1 (en) 2001-11-28
IL144501A0 (en) 2002-05-23
EE200100437A (et) 2002-12-16
HUP0200076A2 (hu) 2002-12-28
MY120601A (en) 2005-11-30
SK287200B6 (sk) 2010-03-08
DE60006649D1 (de) 2003-12-24
CA2360452A1 (en) 2000-08-31
NO320806B1 (no) 2006-01-30
AU771089B2 (en) 2004-03-11
CZ20012991A3 (cs) 2002-01-16
WO2000050423A1 (en) 2000-08-31
AR028815A1 (es) 2003-05-28
ID29829A (id) 2001-10-11
JP4598957B2 (ja) 2010-12-15
UY26024A1 (es) 2000-09-29
CZ301498B6 (cs) 2010-03-24
BG64987B1 (bg) 2006-11-30
PL350179A1 (en) 2002-11-18
HUP0200076A3 (en) 2003-01-28
ATE254615T1 (de) 2003-12-15
DK1157023T3 (da) 2004-03-29
SK10782001A3 (sk) 2002-03-05
PL212545B1 (pl) 2012-10-31
LV12755A (en) 2001-11-20
LT4944B (lt) 2002-08-26
CN1205208C (zh) 2005-06-08
ES2209831T3 (es) 2004-07-01
NO20014017D0 (no) 2001-08-17
GEP20033067B (en) 2003-09-25
LT2001086A (en) 2002-04-25
HK1038923B (en) 2004-03-19
CO5140093A1 (es) 2002-03-22
HK1038923A1 (en) 2002-04-04
CN1341114A (zh) 2002-03-20
BG105830A (en) 2002-03-29
TR200102401T2 (tr) 2001-12-21
NZ513629A (en) 2004-01-30
DE60006649T2 (de) 2004-09-30
PT1157023E (pt) 2004-03-31
KR20010102199A (ko) 2001-11-15
LV12755B (lv) 2002-04-20
BR0008379A (pt) 2002-09-24
MXPA01008374A (es) 2003-06-06
AU3234800A (en) 2000-09-14
RU2253652C2 (ru) 2005-06-10
NO20014017L (no) 2001-10-17

Similar Documents

Publication Publication Date Title
EE04852B1 (et) C-21 modifitseeritud epotioloonid, nende valmistamise meetod ning kasutamine ja ravimkoostise kasutamine vähkkasvajate või teiste proliferatiivsete haiguste ravimisel
IL144294A0 (en) P53 inhibitors and therapeutic use of the same
IL197903A (en) A pharmacovigilance containing riavirus to treat cell culture disorders and its kit
IL151946A0 (en) 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
EE200200118A (et) Terapeutilised kinasoliini derivaadid, nende valmistamise meetod ning kasutamine
HUP0104867A3 (en) Heterocyclic compounds useful in the treatment of inflammatory diseases, process for their preparation, pharmaceutical compositions comprising thereof and their use
AR028426A1 (es) Una composicion farmaceutica y procedimiento de tratamiento de enfermedades de disfunsion cognitiva en un mamifero
AU2072201A (en) Agents and methods for the treatment of proliferative diseases
EE04464B1 (et) Indalüülasendatud benseenkarboksamiidid, nende valmistamismeetod, kasutamine ja farmatseutilised kompositsioonid
EE05109B1 (et) Sulfoonamiidi derivaadid, nende kasutamine meditsiinis ning meetod nende valmistamiseks
EE200100391A (et) Peptidüül-heterotsüklilised ketoonid, nende kasutamine ja farmatseutiline kompositsioon
DE69941996D1 (de) Pharmazeutische zusammenstellung zur verwendung in notbehandlungen und dessen herstellungsverfahren
WO2001049703A3 (en) Substituted sapogenins and their use
EE04497B1 (et) Püridopüranoasepiini derivaadid, nende valmistamine ja terapeutiline kasutamine
MY138883A (en) Use of asiatic acid for treatment of cencer
WO2001028494A3 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
AU2001283285A1 (en) Antimicrobial composition and methods of use in the treatment of disease
EE04490B1 (et) Ühend, selle valmistamise meetod ning kasutamine meditsiinis
WO2001062235A3 (en) A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer
EE05099B1 (et) Bradkardiaalsete toimeainete kasutamine hpertroofiaga seotud mokardiaalsete haiguste ravimiseks ja ravimikombinatsioonid
AU2001270484A1 (en) Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations
EE200300504A (et) 3,7-diasabitsüklo[3.3.1]preparaadid, nende valmistamise meetod ja nimetatud preparaatide kasutaminesüdame arütmiate profülaktikas või ravis
EE200000333A (et) Eesnäärmevähi ravis kasutatav konjugaat ning farmatseutiline kompositsioon ja selle valmistamismeetod
DE69939075D1 (de) Pharmazeutische Zusammenstellung zur Vorbeugung und Behandlung von mit Zellkrankheiten des Augenhintergrundes zusammenhängenden Krankheiten
AU7538700A (en) 5-hydroxysapogenin derivatives with anti-dementia activity

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231